Want to see ZYME full AI Analyst Report?
ZYME Stock Chart & Stats
$22.86
$0.14(0.61%)
At close: 4:00 PM EDT
$22.86
$0.14(0.61%)
Day’s Range― - ―
52-Week Range$12.50 - $29.75
Previous Close$23
Volume259.30K
Average Volume (3M)550.54K
Market Cap
$1.73B
Enterprise Value$1.91K
Total Cash (Recent Filing)$270.70B
Total Debt (Recent Filing)$16.01B
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Nov 10, 2026EPS Estimate
2.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.02
Shares Outstanding70,959,240
10 Day Avg. Volume388,506
30 Day Avg. Volume550,539
Financial Highlights & Ratios
PEG Ratio0.73
Price to Book (P/B)7.39
Price to Sales (P/S)18.72
P/FCF Ratio-57.45
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$40.33Price Target Upside76.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)1.26
Revenue Forecast (FY)$298.07M
Bulls Say, Bears Say
Bulls Say
High Gross Margins And Moderate LeverageSustained ~86% gross margins indicate a high-value antibody engineering platform with strong unit economics; combined with historically conservative leverage (debt-to-equity ~0.20), this provides structural capacity to invest in R&D and absorb near-term losses while preserving the potential for margin expansion as revenues scale.
Material Cash Balance And RunwayA cash reserve north of $400M materially reduces short-term financing dependency and supports multi-year development plans, potential commercialization preparation, and strategic initiatives. This durable liquidity buffer gives management runway to advance clinical programs and execute the Theravance deal without immediate dilutive financing.
Acquisition To Add Recurring Royalties And Cash FlowBuying Theravance is a structural shift toward recurring, commercial cash flows (YUPELRI profit-share, royalties) that diversifies away from milestone-driven income. If completed and integrated, the deal should materially strengthen revenue predictability and free-cash-flow generation over the medium term, supporting R&D funding and capital returns.
Bears Say
Volatile And Sharply Declining RevenueLarge, persistent top-line volatility and a steep TTM decline undermine operating leverage and make long-term planning difficult. Reliance on lumpy partner payments means core revenue durability is weak, complicating efforts to convert strong gross margins into consistent operating profits as scale is not yet established.
Persistent Negative Operating And Free Cash FlowRepeated negative operating and free cash flow show the business routinely consumes cash to fund R&D and operations. Even with a larger cash balance, sustained cash burn increases reliance on milestone receipts, asset sales or financing, elevating execution risk and limiting ability to consistently scale internal programs without partner deals.
Dependence On Partner Milestones And Ex-U.S. Royalty RiskA business model heavily reliant on partners for approvals, milestone payments and royalties reduces revenue control and predictability. Ex-U.S. pricing pressures cited by partners could structurally compress long-term royalty economics, making projected runway and growth contingent on third-party commercial execution.
Zymeworks News
ZYME FAQ
What was Zymeworks’s price range in the past 12 months?
Zymeworks lowest stock price was $12.50 and its highest was $29.75 in the past 12 months.
What is Zymeworks’s market cap?
Zymeworks’s market cap is $1.73B.
When is Zymeworks’s upcoming earnings report date?
Zymeworks’s upcoming earnings report date is Nov 10, 2026 which is in 90 days.
How were Zymeworks’s earnings last quarter?
Zymeworks released its earnings results on Aug 06, 2026. The company reported -$0.62 earnings per share for the quarter, missing the consensus estimate of -$0.562 by -$0.058.
Is Zymeworks overvalued?
According to Wall Street analysts Zymeworks’s price is currently Undervalued.
Does Zymeworks pay dividends?
Zymeworks does not currently pay dividends.
What is Zymeworks’s EPS estimate?
Zymeworks’s EPS estimate is 2.17.
How many shares outstanding does Zymeworks have?
Zymeworks has 70,959,240 shares outstanding.
What happened to Zymeworks’s price movement after its last earnings report?
Zymeworks reported an EPS of -$0.62 in its last earnings report, missing expectations of -$0.562. Following the earnings report the stock price went up 1.773%.
Which hedge fund is a major shareholder of Zymeworks?
Currently, no hedge funds are holding shares in ZYME
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zymeworks Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$40.33 (76.44% Upside)
$40.33 (76.44% Upside)
Blogger Sentiment
Bullish
ZYME Sentiment 80%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 581.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.1%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
63.16%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.80%
Trailing 12-Months
Company Description
Zymeworks
Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.
ZYME Company Deck
ZYME Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed a mixed but cautiously constructive picture: strong scientific and clinical progress (notably the zanatumab regulatory milestones, compelling ZW191 Phase 1 efficacy signals, and an advancing pan‑RAS ADC preclinical platform) and a materially improved cash balance supported by active buybacks and potential milestone upside. Offsetting this, near‑term GAAP performance showed a sharp revenue decline (‑91.1% YoY) and a widened net loss (≈+95.6%), and the company remains dependent on partner milestones and exposed to ex‑U.S. pricing pressures. Pipeline timing risks (e.g., ZW1528 delayed to 2027) and the need for partnerships to scale certain programs temper the near‑term outlook, but management presented credible funding and strategic plans tied to milestones and disciplined capital allocation.View all ZYME earnings summariesZYME Stock 12 Month Forecast
Average Price Target
$40.33
▲(76.44% Upside)
Technical Analysis
Xencor
―
AnaptysBio
―
Vir Biotechnology
―
AbCellera Biologics
―
Generate Biomedicines, Inc.
―
Ownership Overview
1.31% Insiders
8.71% Mutual Funds
3.51% Other Institutional Investors
76.00% Public Companies and
Individual Investors